OR03-2 Phase 1, Randomized, Controlled Trial of GFB-024, a Once-Monthly CB1 Inverse Agonist, in Healthy Overweight and Obese Participants and in Participants with Type 2 Diabetes M...

por Bilic, Sanela, Dagon, Yossi, Gustafson, Thomas, Johnson, Leslie, Lawler, John, Rudolph-Own, Lori, Gaich, Gregory, Tucker, Edwin
Publicado 2022

Safety and Efficacy of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Focal Segmental Glomerulosclerosis, Treatment-Resistant Minimal Change Disease, or Diabetic Nephropathy:...

por Walsh, Liron, Reilly, John F., Cornwall, Caitlin, Gaich, Gregory A., Gipson, Debbie S., Heerspink, Hiddo J.L., Johnson, Leslie, Trachtman, Howard, Tuttle, Katherine R., Farag, Youssef M.K., Padmanabhan, Krishna, Pan-Zhou, Xin-Ru, Woodworth, James R., Czerwiec, Frank S.
Publicado 2021